The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair
The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse
Pelvic organ prolapse (POP) is a common condition in women. Approximately 20% of women undergo surgical correction for POP in their lifetime. Overactive bladder symptoms (OAB) are often associated with POP in 25-69% of patients and POP has been shown to be an independent risk factor for OAB. There is scientific evidence that surgical repair of POP reduces or eliminates OAB in >85%. In addition, stress urinary incontinence (SUI) is also often associated with POP, either clinically evident or as a potential post-operative complication.
The clinical decision as to include a surgical technique to treat SUI when repairing POP surgically is still a matter of controversy. Most surgeons at the institution will include an extra procedure, specifically a retropubic sling, if SUI is clinically evident. Some will not include it unless there is urodynamic or clinical evidence of potential SUI post-operatively. Finally, some will include it regardless of clinical or urodynamic findings based on the apparent high incidence of such SUI after prolapse repair. The Tension-Free-Vaginal Tape (TVT) has been observed to reduce OAB as well as produce de-novo OAB symptoms, so the effect of TVT on OAB is still unclear.
The purpose of this study is to determine the effect of additional TVT surgery on OAB symptoms in patients undergoing POP repair. It is hoped that such data will better determine the effect of either surgical intervention strategy on OAB symptoms. This is a prospective cohort study comparing patients with OAB that undergo surgical repair of their prolapse with or without additional TVT surgery. The outcomes will be measured using pre- and post-operative validated questionnaires (PFDI-20, OAB-q short form).
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Hypothesis: Based on the limited data available, the investigators expect to find that there will be less improvement in OAB symptoms in women undergoing POP surgery with TVT than those undergoing POP surgery alone.
Primary Aim: To determine what effect the addition of a TVT will have on OAB symptoms in women undergoing surgical repair of pelvic organ prolapse using validated questionnaires.
Secondary Aims: To compare postoperative complications between those undergoing prolapse surgery alone and those undergoing prolapse surgery and TVT. Lastly the investigators would like to evaluate comorbidities and potential association to the degree of OAB symptoms
Methods:
Potential eligible subjects will be recruited using information provided by urogynecology staff and by reviewing the upcoming OR schedule. After subjects have been identified, the surgeon will be contacted to confirm whether or not their patient can be contacted by the research team. Only after permission has been communicated from the surgeon to the research team will the team approach the patient about potential participation.
After the patient is consented to participate she will be asked to fill out a PFDI-20 questionnaire. This is a validated questionnaire divided into 3 sections relating to prolapse symptoms, bowel symptoms and urinary symptoms, respectively. It is based on a 5 point scale- 0 for no, and then in terms of how bothersome symptoms are 2- not at all, 3- somewhat, 4- moderately, 5- quite a bit. A higher score indicates greater degree of bother. Focus will be on the UDI-6 section, pertaining to urinary symptoms.
The questions that will determine inclusion or exclusion of the patients are questions 15 and 16: "Do you usually experience frequent urination" and "Do you usually experience urine leakage associated with a feeling of urgency; that is, a strong sensation of needing to go to the bathroom?" Those who respond negatively to these questions will be excluded and those who respond affirmatively to both questions will be included.
The patients with OAB symptoms will be asked to fill out the OAB-q short form validated questionnaire which includes a 6-item symptoms bother scale (OAB-q ss) and a 13-item HRQL scale (OAB-q HRQL). This should be completed pre-operatively and then again 6 weeks, 6 months and 12 months post-operatively.
Interventions: No interventions will be made. This is an observational study.
Outcomes Primary: The primary outcome will be measured using pre- and post-operative validated questionnaires (PFDI-20, OAB-q short form). The primary study endpoint will be the Overactive Bladder Questionnaire Symptom Severity (OAB-q ss) change score 6 weeks after surgery. The change score is the score pre-operatively minus the score post-operatively. A positive score indicates lesser symptoms severity after surgery. The investigators will define a significant improvement to be a change score on the OAB-q ss≥10 based on previous work that determined that the minimally important difference in the OAB-q ss is 10 or higher.
Secondary: The secondary study endpoints will be the OAB-q HRQL change score and the UDI-6 change score calculated using the same method above.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10029
- Mount Sinai Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Women >21 years old with stage 2 or greater pelvic organ prolapse who plan to undergo anterior and/or apical prolapse repair
- Women who respond affirmatively to questions 15 and 16 on the PFDI-20 questionnaire
- Women with negative urine culture pre-operatively
- Women able to provide informed consent
Exclusion Criteria:
- Women with pelvic organ prolapse that respond negatively to questions 15 and 16 on the PFDI-20 questionnaire
- Women with previous urogynecologic surgery including prior hysterectomy with any type of apical support known to the patient (history of hysterectomy alone may be included)
- Women who report UTI within 1 month of recruitment (with confirmation of positive culture)
- Women with history of diagnosis of interstitial cystitis or any treatment for interstitial cystitis
- Women who undergo TVT-O (transobturator) and not retropubic TVT
- Women who undergo posterior compartment repair only
- Women who are pregnant and up to 6 weeks postpartum
- Women who undergo prolapse repair with transvaginal mesh
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Prolapse surgery without TVT
Patients who plan to undergo prolapse repair alone
|
|
Prolapse surgery with TVT
Patients who plan to undergo prolapse repair with an additional TVT procedure
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overactive Bladder Questionnaire (OAB-q short form)
Délai: baseline and 6 weeks
|
Change in the OAB-q score at 6 weeks as compared to baseline.
The OAB-q short form is a validated questionnaire which includes a 6-item symptoms bother scale (OAB-q ss) and a 13-item HRQL scale (OAB-q HRQL)
|
baseline and 6 weeks
|
|
Overactive Bladder Questionnaire (OAB-q short form)
Délai: baseline and 6 months
|
Change in the OAB-q score at 6 months as compared to baseline.
|
baseline and 6 months
|
|
Overactive Bladder Questionnaire (OAB-q short form)
Délai: baseline and 12 months
|
Change in the OAB-q score at 12 months as compared to baseline.
|
baseline and 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
UDI-6 change score
Délai: baseline and 6 weeks
|
Change in the UDI-6 score at 6 weeks as compared to baseline.
UDI-6 is a validated questionnaire pertaining to urinary symptoms.
It is based on a 5 point scale- 0 for no, and then in terms of how bothersome symptoms are 2- not at all, 3- somewhat, 4- moderately, 5- quite a bit.
|
baseline and 6 weeks
|
|
UDI-6 change score
Délai: baseline and 6 months
|
Change in the UDI-6 score at 6 months as compared to baseline.
|
baseline and 6 months
|
|
UDI-6 change score
Délai: baseline and 12 months
|
Change in the UDI-6 score at 12 months as compared to baseline.
|
baseline and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Charles Ascher-Walsh, MD, Icahn School of Medicine at Mount Sinai
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GCO 15-0394
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .